Cytokines in cancer pathogenesis and cancer therapy

Nature Reviews Cancer

Volumn 4, Issue 1, 2004, Pages 11-22

  Dranoff, Glenn ^a,b  

^a Dana Farber Cancer Institute   (United Kingdom)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; ALPHA INTERFERON; BETA CHEMOKINE; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR4; COLONY STIMULATING FACTOR 1; CX3C CHEMOKINE; CYTOKINE; FLT3 LIGAND; GAMMA CHEMOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; LYMPHOTACTIN; NITRIC OXIDE SYNTHASE; PERFORIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG;

ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CLINICAL TRIAL; CYTOKINE PRODUCTION; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; CANCER RESEARCH; MEDICAL LITERATURE; PUBLICATION; IMMUNOLOGY; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY;

CYTOKINES; HUMANS; NEOPLASMS;

EID: 0347302952     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc1252     Document Type: Review

References (141)

1. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell100, 57-70 (2000).
2. Liotta, L. A. & Kohn, E. C. The microenvironment of the tumour-host interface. Nature411, 375-379 (2001).
3. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med. 1, 27-31 (1995).
4. Clark, W. et al. Model predicting survival in stage I melanoma based on tumor progression. J. Natl. Cancer Inst. 81, 1893-1904 (1989).
5. Clemente, C. et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer77, 1303-1310 (1996).
6. Naito, Y. et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58, 3491-3494 (1998).
7. Nakano, O. et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 61, 5132-5136 (2001).
8. Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Eng. J. Med. 348, 203-213(2003).
9. Dunn, G., Bruce, A., Ikeda, H., Old, L. & Schreiber, R. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol. 3, 991-998 (2002).
10. Ames, B. N., Gold, L. S. & Willett, W. C. The causes and prevention of cancer. Proc. Natl Acad. Sci. USA92, 5258-5265 (1995).
11. Coussens, L. & Werb, Z. Inflammation and cancer. Nature420, 860-867 (2002).
12. Ochsenbein, A. F. et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411, 1058-1064 (2001).
13. Dranoff, G. & Mulligan, R. C. Gene transfer as cancer therapy. Adv. Immunol. 58, 417-454 (1995).
14. Paul, W. E. Pleiotropy and redundancy: T cell-derived lymphokines in the immune response. Cell57, 521-524(1989).
15. Janeway, C. A. Jr. How the immune system works to protect the host from infection: a personal view. Proc. Natl Acad. Scl. USA98, 7461-7468 (2001).
16. Zinkernagel, R. M. On natural and artificial vaccinations. Annu. Rev. Immunol. 21, 515-546 (2003).
17. Diefenbach, A. & Raulet, D. The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol. Rev. 188, 9-21 (2002).
18. Karre, K. NK cells, MHC class I molecules and the missing self. Scan. J. Immunol. 55, 221-228 (2002).
19. Albert, M. et al. Immature dendritic cells phagocytose apoptotic cells via avp5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188, 1359-1368 (1998).
20. Basu, S., Binder, R. J., Ramalingam, T. & Srivastava, P. K. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity14, 303-313 (2001).
21. Sharpe, A. H. & Freeman, G. J. The B7-CD28 superfamily. Nature Rev. Immunol. 2, 116-126 (2002).
22. Banchereau, J. & Steinman, R. Dendritic cells and the control of immunity. Nature392, 245-252 (1998).
23. Boon, T. & van der Bruggen, P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183, 725-729 (1996).
24. Old, L. & Chen, Y.-T. New paths in human cancer serology. J. Exp. Med. 187, 1163-1167 (1998).
25. Sahin, U. et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl Acad. Sci. USA92, 11810-11813 (1995).
26. Marincola, F. M., Jaffee, E. M., Hicklin, D. J. & Ferrone, S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74, 181-273 (2000).
27. Kaplan, D. et al. Demonstration of an interferon y-dependent tumor surveillance system in immunocompetent mice. Proc. Natl Acad. Sci. USA95, 7556-7561 (1998).
28. Street, S. E., Cretney, E. & Smyth, M. J. Perforin and interferon-y activities independently control tumor initiation, growth, and metastasis. Blood97, 192-197 (2001).
29. Qin, Z., Kim, H. J., Hemme, J. & Blankenstein, T. Inhibition of methylcholanthrene-induced carcinogenesis by an interferon y receptor-dependent foreign body reaction. J. Exp. Med. 195, 1479-1490 (2002).
30. Bach, E. A., Aguet, M. & Schreiber, R. D. The IFNy receptor: a paradigm for cytokine receptor signaling. Annu. Rev. Immunol. 15, 563-591 (1997).
31. Smyth, M. et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191, 661-668 (2000).
32. Shankaran, V. et al. IFNy and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature410, 1107-1111 (2001).
33. This study delineates an increased incidence of spontaneous carcinomas in mice deficient in Statl and Rag2.
34. Girardi, M. et al. Regulation of cutaneous malignancy by yS T cells. Science294, 605-609 (2001).
35. Girardi, M. et al. Resident skin-specific γδ T cells provide local, nonredundant regulation of cutaneous inflammation. J. Exp. Med. 195, 855-867 (2002).
36. Gao, Y et al. γδ T cells provide an early source of interferon y in tumor immunity. J. Exp. Med. 198, 433-442(2003).
37. van den Broek, M. et al. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 184, 1781-1790(1996).
38. Takeda, K. et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. 195, 161-169(2002).
39. Smyth, M. et al. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J. Exp. Med. 192, 755-760 (2000).
40. Street, S. E., Trapani, J. A., MacGregor, D. & Smyth, M. J.: Suppression of lymphoma and epithelial malignancies effected by interferon yJ. Exp. Med. 196, 129-134 (2002).
41. Davidson, W., Giese, T. & Fredrickson, T. Spontaneous development of plasmacytoid tumors in mice with defective fas-fas ligand interactions. J. Exp. Med. 187, 1825-1838 (1998).
42. Siegel, R. M., Chan, F. K., Chun, H. J. & Lenardo, M. J. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nature Immunol. 1, 469-474 (2000).
43. Enzler, T.: Deficiencies of GM-CSF and interferon-y link inflammation and cancer. J. Exp. Med. 197, 1213-1219(2003).
44. This study delineates a crucial role for microbial agents in the spontaneous development of lymphomas and solid tumors in Gm-csf//fn-ydeficient mice.
45. Kado, S.: Intestinal microflora are necessary for development of spontaneous adenocarcinoma of the large intestine in T-cell receptor p chain and p53 double-knockout mice. Cancer Res. 61, 2395-2398 (2001).
46. Engle, S. J. et al. Elimination of colon cancer in germ-free transforming growth factor p1-deficient mice. Cancer Res. 62, 6362-6366 (2002).
47. Penn, I. Depressed immunity and the development of cancer. Cancer Detect. Prev. 18, 241-252 (1994).
48. Kuper, H., Adami, H. O. & Trichopoulos, D. Infections as a major preventable cause of human cancer. J. Intern. Med. 248, 171-183 (2000).
49. Pisani, P., Parkin, D. M., Munoz, N. & Ferlay, J. Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol. Biomarkers Prev. 6, 387-400 (1997).
50. El-Omar, E. M.: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404, 398-402 (2000).
51. Nakamoto, Y., Guidotti, L. G., Kuhlen, C. V., Fowler, P & Chisari, F. V. Immune pathogenesis of hepatocellular carcinoma. J. Exp. Med. 188, 341-350 (1998).
52. Nakamoto, Y: Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-fas ligand antibody therapy. J. Exp. Med. 196, 1105-1111(2002).
53. Daniel, D.: Immune enhancement of skin carcinogenesis by CD4+T cells. J. Exp. Med. 197, 1017-1028 (2003).
54. Fehniger, T.: Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J. Exp. Med. 193, 219-231 (2001).
55. Hudson, J.: A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med. 190, 1375-1382 (1999).
56. Moore, R. J.: Mice deficient in tumor necrosis factor-a are resistant to skin carcinogenesis. Nature Med. 5, 828-831 (1999).
57. Hilbert, D. M., Kopf, M., Mock, B. A., Kohler, G. & Rudikoff, S. Interleukin 6 is essential for in vivo development of B lineage neoplasms. J. Exp. Med. 182, 243-248 (1995).
58. Lattanzio, G.: Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. Am. J. Pathol. 151, 689-696 (1997).
59. Lin, E., Nguyen, A., Russell, R. & Pollard, J. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193, 727-739 (2001).
60. Voronov, E.: IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl Acad. Sci. USA100, 2645-2650(2003).
61. Coussens, L. M., Tinkle, C. L., Hanahan, D. & Werb, Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell103, 481-490 (2000).
62. This study demonstrates that immune cells can promote tumour formation and progression.
63. Muller, A.: Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56 (2001).
64. Steinbach, G.: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Eng. J. Med. 342, 1946-1952 (2000).
65. Jacoby, R. F., Seibert, K., Cole, C. E., Kelloff, G. & Lubet, R. A. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res. 60, 5040-5044 (2000).
66. Nauts, H., Fowler, G. & Bogatko, F.: A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley's mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study. Acta Med. Scand. 144, S1-S103 (1953).
67. This report documents durable clinical remissions in response to mixed bacterial toxins. Interferon a versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. J. Natl. Cancer Inst. 89, 1616-1620 (1997).
68. Kirkwood, J. etal. Interferon a-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14, 7-17 (1996).
69. Kirkwood, J. M. et al. High-dose interferon a-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J. Clln. Oncol. 19, 2370-2380 (2001).
70. Fyfe, G.: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clln. Oncol. 13, 688-696 (1995).
71. Rosenberg, S. A.: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst. 85, 622-632 (1993).
72. Soiffer, R. J.: Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2. Clln. Cancer Res. 2, 493-499 (1996).
73. Furtado, G. C., Curotto de Lafaille, M. A., Kutchukhidze, N. & Lafaille, J. J. Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J. Exp. Med. 196, 851-857 (2002).
74. Lienard, D., Ewalenko, P., Delmotte, J. J., Renard, N. & Lejeune, F. J. High-dose recombinant tumor necrosis factor a in combination with interferon y and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol. 10, 52-60 (1992).
75. Atkins, M. B. et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clln. Cancer Res. 3, 409-417 (1997).
76. Spitler, L. E. et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J. Clln. Oncol. 18, 1614-1621 (2000).
77. Rini, B. I., Weinberg, V., Bok, R. & Small, E. J. Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J. Clin. Oncol. 21, 99-105 (2003).
78. Anderson, P M. et al. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin. Cancer Res. 5, 2316-2323 (1999).
79. Lieschke, G. J. & Burgess, A. W. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N. Eng. J. Med. 327, 28-35, 99-106 (1992).
80. Demetri, G. D., Kris, M., Wade, J., Degos, L. & Cella, D. Quality-of-life benefit in chemotherapy patients treated with epoetin a is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J. Clln. Oncol. 16, 3412-3425 (1998).
81. Forni, G. et al. Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy. Cancer Metast. Rev. 7, 289-309 (1988).
82. Dranoff, G. et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Scl. USA90, 3539-3543 (1993).
83. Cavallo, F. et al. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J. Natl. Cancer Inst:. 89, 1049-1058 (1997).
84. Boggio, K. et al. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinoma in two lines of her-2/neu transgenic mice. J. Exp. Med. 188, 589-596 (1998).
85. Mach, N. et al. Differences in dendritic cells stimulated ln vlvo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or flt3-ligand. Cancer Res. 60, 3239-3246 (2000).
86. Gillessen, S. et al. CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion. Proc. Natl Acad. Scl. USA100, 8874-8879 (2003).
87. Hung, K.: The central role of CD4+ T cells in the antitumor immune response. J. Exp. Med. 188, 2357-2368 (1998).
88. Reilly, R.: The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res. 61, 880-883 (2001).
89. Curcio, C.: Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J. Clln. Invest. 111, 1161-1170 (2003).
90. Mach, N. & Dranoff, G. Cytokine-secreting tumor cell vaccines. Curr. Opln. Immunol. 12, 571-575 (2000).
91. Soiffer, R. et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor generates potent anti-tumor immunity in patients with metastatic melanoma. Proc. Natl Acad. Scl. USA95, 13141-13146 (1998).
92. Schmollinger, J. C. et al. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc. Natl Acad. Scl. USA100, 3398-3403(2003).
93. Hodi, F. S. et al. ATP6S1 elicits potent humoral responses associated with immune mediated tumor destruction. Proc. Natl Acad. Scl. USA99, 6919-6924 (2002).
94. Mollick, J. A., Hodi, F. S., Soifer, R. J., Nadler, L. M. & Dranoff, G. MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients. Cancer Immun. 3, 3-20(2003).
95. Simons, J. W. et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vlvo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 57, 1537-1546 (1997).
96. Simons, J. et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vlvo gene transfer. Cancer Res. 59, 5160-5168 (1999).
97. Zehnter, S. et al. Tumor metastasis biopsy as a surrogate marker of response to melanoma immunotherapy. Pathology 31, 116-122 (1999).
98. Shenk, T. in Flelds Vlrology(eds Fields, B. N., Knipe, D. M. & Howley, P M.) 2111-2148 (Lippincott-Raven Publishers, Philadelphia, 1996).
99. Salgia, R. et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J. Clln. Oncol. 21, 624-630 (2003).
100. Borrello, I., Sotomayor, E., Cooke, S. & Levitsky, H. A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum. Gene Ther. 10, 1983-1991 (1999).
101. Jaffee, E. et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J. Clln. Oncol. 19, 145-156 (2001).
102. Chambers, C. A., Kuhns, M. S., Egen, J. G. & Allison, J. P CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 19, 565-594 (2001).
103. Doyle, A. M. et al. Induction of cytotoxic T lymphocyte antigen 4 (CTLA-4) restricts clonal expansion of helper T cells. J. Exp. Med. 194, 893-902 (2001).
104. Salomon, B. & Bluestone, J. A. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19, 225-252 (2001).
105. Shevach, E. M., McHugh, R. S., Piccirillo, C. A. & Thornton, A. M. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol. Rev. 182, 58-67 (2001).
106. van Elsas, A., Hurwitz, A. & Allison, J. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190, 355-366 (1999).
107. Sutmuller, R. P. et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194, 823-832(2001).
108. Waterhouse, P. et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270, 985-988 (1995).
109. Tivol, E. A. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunlty3, 541-547 (1995).
110. Phan, G. Q. et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Scl. USA100, 8372-8377 (2003).
111. Hodi, F. S. et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl Acad. Scl. USA100, 4712-4717(2003).
112. This study, together with reference 107, indicates that CTLA-4 antibody blockade can be combined with cancer vaccines to increase tumour immunity in patients, albeit with a risk of compromising tolerance to self-antigens.
113. Herr, H. et al. Intravesical bacille Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J. Clln. Oncol. 13, 1404-1408 (1995).
114. This study demonstrates that the therapeutic administration of a mycobacteria reduces morbidity and mortality of bladder carcinoma.
115. Driggers, P H., Elenbaas, B. A., An, J. B., Lee, I. J. & Ozato, K. Two upstream elements activate transcription of a major histocompatibility complex class I gene ln vltro. Nuc. Aclds Res. 20, 2533-2540 (1992).
116. Holtschke, T. et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell87, 307-317 (1996).
117. Hao, S. X. & Ren, R. Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder Mol. Cell Blol. 20, 1149-1161 (2000).
118. Schiavoni, G. et al. ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8a(+) dendritic cells. J. Exp. Med. 196, 1415-1425 (2002).
119. Schmidt, M. et al. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood91, 22-29 (1998).
120. Takaoka, A. et al. Integration of interferon-a/p signalling to p53 responses in tumour suppression and antiviral defence. Nature424, 516-523 (2003).
121. Molldrem, J. et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nature Med. 6, 1018-1023 (2000).
122. Molldrem, J. J. et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J. Clln. Invest. 111, 639-647 (2003).
123. Fearon, E. R. et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60, 397-403 (1990).
124. Gansbacher, B. et al. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172, 1217-1224 (1990).
125. Pulaski, B. A. et al. Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex re-presentation of exogenous antigen by tumor-infiltrating antigen-presenting cells. Proc. Natl Acad. Scl. USA93, 3669-3674 (1996).
126. Tepper, R. I., Coffman, R. L. & Leder, P An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Sclence 257, 548-551 (1992).
127. Golumbek, P. T. et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science254, 713-716 (1991).
128. Nishimoto, N. et al. Improvement in Castleman''s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95, 56-61 (2000).
129. Hock, H., Dorsch, M., Diamanstein, T. & Blankenstein, T. Interleukin-7 induces CD4+ T cell-dependent tumor rejection. J. Exp. Med. 174, 1291-1298 (1991).
130. Qin, Z., Noffz, G., Mohaupt, M. & Blankenstein, T. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J. Immunol. 159, 770-776 (1997).
131. Brunda, M. J. et al. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J. Exp. Med. 178, 1223-1230 (1993).
132. Terabe, M. et al.NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nature Immunol. 1, 515-520 (2000).
133. Hazama, S. et al. Tumour cells engineered to secrete interleukin-15 augment anti-tumour immune responses In vivo. Br. J. Cancer 80, 1420-1426 (1999).
134. Micallef, M. J., Tanimoto, T., Kohno, K., Ikeda, M. & Kurimoto, M. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma. Cancer Res. 57, 4557-4563 (1997).
135. Jakubowski, A. A. et al. Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanoma. Clin. Cancer Res. 2, 295-302 (1996).
136. Biron, C. A. Interferons a and p as immune regulators: a new look. Immunity14, 661-664 (2001).
137. Tracey, K. J. & Cerami, A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu. Rev. Med. 45, 491-503 (1994).
138. Walczak, H. et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature Med. 5, 157-163 (1999).
139. Lynch, D. et al. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nature Med. 3, 625-631 (1997).
140. Rousseau, R. F. et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood101, 1718-1726(2003).
141. Gorelik, L. & Flavell, R. A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-p signaling in T cells. Nature Med. 7, 1118-1122 (2001).